You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SPNS2 inhibitors as renal fibrosis therapy

    SBC: Flux Therapeutics, LLC            Topic: 400

    Fibrosis is an aberrant wound healing process characterized by progressive accumulation of extracellular matrix that ultimately destroys organ function. Progressive fibrosis is inherent to chronic kidney disease (CKD), which often leads to end-stage renal disease. Although patients can be maintained by hemodialysis while awaiting transplantation, their’s and their care-giver’s quality of life ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Novel probiotics to mitigate xenobiotic toxicity through microbial biotransformation

    SBC: NEXILICO, INC.            Topic: NIEHS

    PROJECT SUMMARY / ABSTRACT The human gut microbiome consists of trillions of microorganisms which metabolize a variety of xenobiotic compounds, including environmental chemicals, thereby affecting their overall toxicity to the host organism. Gut microorganisms can either increase or decrease the toxicity of xenobiotic compounds based on reactions with microbial enzymes, which is referred to as Mic ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Prevention and mitigation of acute traumatic coagulopathy and bleeding

    SBC: HEMATHERIX LLC            Topic: NHLBI

    Project Summary/Abstract Hematherix is developing superFVa for the treatment of acute traumatic coagulopathy (ATC). Mortality rates with traumatic hemorrhage often exceed 40%, exposing an unmet clinical need for targeted drug development. ATC develops early on as the consequence of severe trauma and shock, prior to additional iatrogenic effects. ATC is distinct from other coagulopathies and is cha ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting TLR4-lipid rafts to prevent postoperative pain

    SBC: RAFT PHARMACEUTICALS LLC            Topic: 108

    PROJECT SUMMARY Postoperative pain is a prevalent source of pain requiring appropriate management to reduce its impact upon quality of life. Even with the availability of several analgesics, postoperative pain is often undermedicated because of concern related to the adverse consequence of the available therapeutics (e.g., NSAIDs and opiates), including addiction and decreased survival of cancer p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Therapeutic targeting of FKBP51 for the prevention of stress-induced preterm birth

    SBC: DARE BIOSCIENCE, INC.            Topic: NICHD

    In the United States, one in ten babies is born prematurely. The earlier in pregnancy a baby is born, the more likely they will have an extended hospital stay, as well as serious health complications such as respiratory distress syndrome, necrotizing enterocolitis, deafness, vision problems and cerebral palsy. Maternal stress is a well-established risk factor for preterm birth, and recent studies ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Therapeutic to Promote Corneal Repair

    SBC: MICROCURES INC            Topic: NEI

    The cornea is one of the most important tissues in the eye and its transparency is critical for good visual function in humans. Corneal tissue injuries are the most common, everyday issue for practicing ophthalmologists and can run the gamut in severity. Healing of large corneal wounds, such as alkali burns, involves extended migration of epithelial cells as well as reinnervation of the cornea. Ho ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Substance Use Disorder Artificially Intelligent chatbot for screening, assessment and referral: SUD Bot

    SBC: Clinic Chat LLC            Topic: NIDA

    ABSTRACT The opioid epidemic is considered one of the most severe public health crises we are facing in the U.S. and is worsened by use of stimulants such as methamphetamine. The US Preventive Services Task Force (USPSTF) recommends screening for unhealthy drug use accompanied by offers of and referrals to services that include accurate diagnosis, effective treatment and appropriate care of a subs ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Image-based risk assessment to identify women at high-risk for breast cancer

    SBC: WAVED MEDICAL LLC            Topic: NCI

    7. PROJECT SUMMARY Breast cancer is the most common cancer worldwide and the most common cancer diagnosed in American women. While there has been good progress regarding detection and treatment methods, breast cancer remains the primary cause of death from malignant tumors. Hence, there is a critical need for the development of novel predictive and prognostic factors. Risk assessments are currentl ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects

    SBC: General Biophysics LLC            Topic: NIA

    PHASE II APPLICATION(STTR Program PAS-22-197) “Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects” ABSTRACTAlzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant role in the onset an ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government